Bausch Health Companies

Gastroenterology Expansion And Global Markets Will Unlock Opportunities

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 May 25

AnalystConsensusTarget's Fair Value

US$7.08

14.6% undervalued

04 Sep

US$6.05

-25.9%

You can edit this narrative until May 12 6:00 AM. Then, changes will post as Updates.

Author's Valuation

US$7.0814.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$7.08

14.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-0.45%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

11.50%

Calculation

US$264.36m

Earnings '28

13.93x

PE Ratio '28

US$3.68b

Market Cap '28

US$3.68b

Market Cap '28

375.82m

No. shares '28

US$9.80

Share Price '28

US$9.80 Share Price '28

Discounted to 2025 @ 11.50% p.a.

US$7.07

Fair Value '25